These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35284102)

  • 1. A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.
    Awosika J; Sohal D
    J Gastrointest Oncol; 2022 Feb; 13(1):426-437. PubMed ID: 35284102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in advanced hepatocellular carcinoma.
    Medavaram S; Zhang Y
    Exp Hematol Oncol; 2018; 7():17. PubMed ID: 30087805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional and systemic therapy for hepatocellular carcinoma.
    Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
    J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in multidisciplinary management of hepatocellular carcinoma.
    Gomaa AI; Waked I
    World J Hepatol; 2015 Apr; 7(4):673-87. PubMed ID: 25866604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options.
    Ghavimi S; Apfel T; Azimi H; Persaud A; Pyrsopoulos NT
    J Clin Transl Hepatol; 2020 Jun; 8(2):168-176. PubMed ID: 32832397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.
    Ray EM; Sanoff HK
    J Hepatocell Carcinoma; 2017; 4():131-138. PubMed ID: 29184856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma: a review.
    Balogh J; Victor D; Asham EH; Burroughs SG; Boktour M; Saharia A; Li X; Ghobrial RM; Monsour HP
    J Hepatocell Carcinoma; 2016; 3():41-53. PubMed ID: 27785449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
    Yegin EG; Oymaci E; Karatay E; Coker A
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.